Olfactory training with patients suffering from depressive disorders

Organizational Data

DRKS-ID:
DRKS00016350
Recruitment Status:
Recruiting complete, study complete
Date of registration in DRKS:
2018-12-19
Last update in DRKS:
2021-01-12
Registration type:
Retrospective

Acronym/abbreviation of the study

OTDD

URL of the study

No Entry

Brief summary in lay language

We invited 102 patients suffering from depression to take part in a "smell training", smelling on four bottled odors daily for a time-period of four months to see if it helps reduce depressive symptoms and compared this effect to a depressive control Group that solved sudokus in the same time period.

Brief summary in scientific language

By means of a randomized controlled intervention study, we investigated whether olfactory training is a useful complementary strategy for depression treatment in a sample of 102 depressive out-patients.

Health condition or problem studied

ICD10:
F32 - Depressive episode
ICD10:
F33 - Recurrent depressive disorder
ICD10:
F43.2 - Adjustment disorders
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
Experimental group: Depressive Patients diagnosed with F32, F33 and F43.2 completed an olfactory Training over a time-period of 16 weeks. This daily short-time exposure comprised smelling on the four bottled odors rose, lime, eucalyptus and glove and rating intensity of the odors, mood and energy level in a "smell diary" once a week.
Arm 2:
Control group: Depressive Patients diagnosed with F32, F33 and F43.2 completed a "cognitive Training" over a time-period of 16 weeks. This comprised solving sudokus twice a day for five minutes and rating perceived difficulty of the task, as well as mood and energy level in a "Sudoku diary" once a week.

Endpoints

Primary outcome:
We aimed to investigate in a sample of clinically depressed patients whether Olfactory Training (OT) has a positive effect on depressive symptoms, compared to a placebo training, which we expected not to show any beneficial effect. In line with the previous research in this field, we furthermore hypothesized that OT improves olfactory function and, as a “side effect”, cognitive function. On average, the post-test appointment was arranged 16 weeks after pre-test. The participants had to fullfill the Training on a regular Basis at least for 12 weeks to be included in the statistical data analysis. Depressive symptoms were assessed using the Beck Depression Inventory (BDI-II; Beck et al., 1996; Hautzinger, Keller, & Kühner, 2006). Additionally, the 36-item Short Form Health Survey (SF-36) (Bullinger et al., 1995) was applied in the pre-test to measure health-related quality of life. Olfactory function in terms of odor threshold and identification ability was measured with a validated and reliable forced choice paradigm using the Sniffin’ Sticks testing kit (Burghart GmbH, for a detailed description see (Hummel, Sekinger, Wolf, Pauli, & Kobal, 1997)). In addition to the assessment of objective olfactory function, we also asked our participants about their individual importance of olfaction with a questionnaire (Croy, Buschhüter, Seo, Negoias, & Hummel, 2010). In order to control for a potential cognitive impact on olfactory function and affective disorders, two cognitive tests were performed with the participants: The revised d2 attention and concentration test (Brickenkamp & Zillmer, 1998), and the Regensburger verbal fluency test (RWT; Aschenbrenner, Tucha, & Lange, 2000). In order to control for potential confounders accompanying diseases, we included a medical history questionnaire. The recruitment ran continuosly between November 2015 and September 2017, so that the post-test data of the last participant was collected in September 2017.
Secondary outcome:
In the same sample of depressive out-patients, we examined the influence of severity, course and duration of depression on olfactory function. We expected severity, course and duration of depression affecting olfactory function in terms of a reduction in olfactory function (odor identification and odor threshold). We used the same methods as described above to examine this research question. Furthermore, we divided the sample into three sub-groups, taking the BDI score, the diagnoses (F32 vs. F33) and duration of depression into account.

Study Design

Purpose:
Treatment
Allocation:
Randomized controlled study
Control:
  • Placebo
Phase:
N/A
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
No
Assignment:
Parallel
Sequence generation:
No Entry
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting complete, study complete
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Monocenter study
Recruitment location(s):
  • University medical center Klinik für Psychotherapie und Psychosomatik Dresden

Recruitment period and number of participants

Planned study start date:
No Entry
Actual study start date:
2015-11-05
Planned study completion date:
No Entry
Actual Study Completion Date:
2017-09-02
Target Sample Size:
121
Final Sample Size:
102

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
99 Years
Additional Inclusion Criteria:
Symptoms of an at least mild depression (BDI-score >13 and <20) served as inclusion criterion. Sufficient German skills and an age of >17 yrs were also mandatory.

Exclusion Criteria

Exclusion criteria were diagnosed anosmia, chronic nasal diseases, neurodegenerative diseases, and metabolic diseases, as well as being currently affected with acute respiratory diseases like colds and influenza, although frequent respiratory diseases in their medical history were not an exclusion criterion. Furthermore, current psychological treatment, antidepressant medication or the admission into psychotherapeutic treatment facilities during the course of training was not an exclusion criterion due to ethical reasons, but was taken into account for in the statistical data Analysis.

Addresses

Primary Sponsor

Address:
Klinik für Psychotherapie und Psychosomatik Universitätsklinikum Carl Gustav Carus
Jun.-Prof. Ilona Croy
Fetscherstr. 74
01307 Dresden
Germany
Telephone:
0049-351-458-3502
Fax:
0049-351-458-5713
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.uniklinikum-dresden.de
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Klinik für Psychotherapie und PsychosomatikUniversitätsklinikum Carl Gustav Carus Dresden
Dipl.-Psych. Luise Pabel
Fetscherstr. 74
01307 Dresden
Germany
Telephone:
0049-351-458-17079
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.uniklinikum-dresden.de

Contact for Public Queries

Address:
Klinik für Psychotherapie und PsychosomatikUniversitätsklinikum Carl Gustav Carus
Dipl.-Psych. Luise Pabel
Fetscherstr. 74
01307 Dresden
Germany
Telephone:
0049-351-458-17079
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.uniklinikum-dresden.de

Principal Investigator

Address:
Klinik für Psychotherapie und PsychosomatikUniversitätsklinikum Carl Gustav Carus Dresden
Dipl.-Psych. Luise Pabel
Fetscherstr. 74
01307 Dresden
Germany
Telephone:
0049-351-458-17079
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.uniklinikum-dresden.de

Sources of Monetary or Material Support

Private sponsorship (foundations, study societies, etc.)

Address:
Medizinische Fakultät
Fetscherstr. 74
01307 Dresden
Germany
Telephone:
0049-351 458-3306
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://tu-dresden.de/med/mf/forschung/services-fuer-forschende/foerderprogramme-fuer-nachwuchswissenschaftler/meddrive

Ethics Committee

Address Ethics Committee

Address:
Ethikkommission an der TU Dresden
Fetscherstr. 74
01307 Dresden
Germany
Telephone:
+49-351-4582992
Fax:
+49-351-4584369
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2015-01-19
Ethics committee number:
EK48022015
Vote of the Ethics Committee:
Approved
Date of the vote:
2015-02-03

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No Entry
IPD Sharing Plan:
No Entry

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry